Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20243525 | 0.83 | GRM5 (0.40) | GRM5KMT2AGRM2KMOJAK3 | |
| SCHEMBL24350030 | 0.83 | JAK3 (0.35) | GRM5KMOJAK3 | |
| SCHEMBL3408536 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HTTGRM5KDM4ENPC1 | |
| SCHEMBL18005387 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HTTGRM5KDM4ENPC1 | |
| SCHEMBL26478041 | 0.79 | GRM5 (0.39) | GRM5GRM2KMO | |
| SCHEMBL20260103 | 0.73 | GRM5 (0.51) | GRM5 | |
| SCHEMBL2014472 | 0.72 | KMO (0.40) | GRM5KMO | |
| SCHEMBL5075117 | 0.71 | JAK3 (0.47) | GRM5JAK3 | |
| SCHEMBL2131428 | 0.70 | ALDH1A1 (0.70) | ALDH1A1HTTKDM4ENPC1RAB9A | |
| SCHEMBL23907998 | 0.70 | KMT2A (0.44) | ALDH1A1HTTGRM5KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962834-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2257541-B1 | MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | HOFFMANN-LA ROCHE INC. (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2257541-A1 | MODULATORS FOR AMYLOID BETA | F. Hoffmann-La Roche AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | HOFFMANN-LA ROCHE, INC. | 2009-08-27 | — | — | US | disclosed |
| WO-2009103652-A1 | MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215759-A1 | MODULATORS FOR AMYLOID BETA | APP, PSEN1, APOB | ALDH1A1 2956/4885HTT 22/4885GRM5 4105/4885 |
| US-20130190302-A1 | MODULATORS OF AMYLOID BETA | APP, PSEN1, APOB | ALDH1A1 2860/4885HTT 19/4885GRM5 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.